Alicyn Campbell

1.5k total citations
15 papers, 493 citations indexed

About

Alicyn Campbell is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Economics and Econometrics. According to data from OpenAlex, Alicyn Campbell has authored 15 papers receiving a total of 493 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 2 papers in Economics and Econometrics. Recurrent topics in Alicyn Campbell's work include Lung Cancer Treatments and Mutations (7 papers), Colorectal Cancer Treatments and Studies (5 papers) and HER2/EGFR in Cancer Research (3 papers). Alicyn Campbell is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Colorectal Cancer Treatments and Studies (5 papers) and HER2/EGFR in Cancer Research (3 papers). Alicyn Campbell collaborates with scholars based in United States, United Kingdom and South Korea. Alicyn Campbell's co-authors include Joseph O’Connell, Ian W. Taylor, Stephen P. Letrent, Ana Ruiz-Garcı́a, Jane Liang, Dae Seog Heo, Keunchil Park, Denis Talbot, Carlos H. Barrios and Suresh S. Ramalingam and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

Alicyn Campbell

15 papers receiving 477 citations

Peers

Countries citing papers authored by Alicyn Campbell

Since Specialization

Citations

This map shows the geographic impact of Alicyn Campbell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alicyn Campbell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alicyn Campbell more than expected).

Fields of papers citing papers by Alicyn Campbell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alicyn Campbell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alicyn Campbell. The network helps show where Alicyn Campbell may publish in the future.

Co-authorship network of co-authors of Alicyn Campbell

This figure shows the co-authorship network connecting the top 25 collaborators of Alicyn Campbell. A scholar is included among the top collaborators of Alicyn Campbell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alicyn Campbell. Alicyn Campbell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Implementation of digital health technology in clinical trials: the 6R framework 2023 ·Nature Medicine ·(unknown), (unknown), Elisabeth Björk, Rod Hughes, Serban Ghiorghiu, Cristian Massacesi, Alicyn Campbell, Emmette R. Hutchison, Menelas N. Pangalos, Susan Galbraith	8
2	Epidemiology of interstitial lung disease in patients with metastatic breast cancer at baseline and after treatment with HER2-directed therapy: a real-world data analysis 2022 ·Breast Cancer Research and Treatment ·(unknown), Alicyn Campbell, (unknown), Colden Johanson, (unknown), Elisabeth Piault, Monika A. Izano, Anette Schrag, (unknown), Thomas D. Brown, Henry G. Kaplan	4
3	Use of Patient-Reported Outcomes to Understand & Measure the Patient Experience of Novel Cell and Gene Therapies 2020 ·Therapeutic Innovation & Regulatory Science ·(unknown), Alicyn Campbell, Ethan Basch, Stacie Hudgens, Mark Stewart, James J. Wu, Allison Barz Leahy, Jeff Allen	7
4	Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events: Methods for item selection in industry-sponsored oncology clinical trials 2018 ·Clinical Trials ·Peter C. Trask, Amylou C. Dueck, Elisabeth Piault, Alicyn Campbell	24
5	Validation of a treatment satisfaction questionnaire in non-Hodgkin lymphoma: assessing the change from intravenous to subcutaneous administration of rituximab 2016 ·Patient Preference and Adherence ·Christina Theodore‐Oklota, L. Humphrey, (unknown), Gabriel Schnetzler, Stacie Hudgens, Alicyn Campbell	12
6	1809 Results of the OPTIMA (Optimal Personalized Treatment of early breast cancer usIng Multi-parameter Analysis) prelim study 2015 ·European Journal of Cancer ·Robert C. Stein, (unknown), Luke Hughes‐Davies, J. M. S. Bartlett, A. Marshall, Peter Hall, Alicyn Campbell, S Pinder, David Cameron, D. Rea, Helena Earl, (unknown), (unknown), Peter Canney, (unknown), (unknown), Nigel Stallard, Claire Hulme, Christopher J. McCabe, Janet Dunn	2
7	Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non–Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib: A Phase I/II Trial 2014 ·Journal of Thoracic Oncology ·Keunchil Park, Byoung Chul Cho, Dong‐Wan Kim, Myung‐Ju Ahn, Sang Yoon Lee, Diana Gernhardt, Ian W. Taylor, Alicyn Campbell, Hui Zhang, Nagdeep Giri, Stephen P. Letrent, Joseph O’Connell, Dae Seog Heo	20
8	A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib 2014 ·Cancer ·Karen L. Reckamp, Giuseppe Giaccone, D. Ross Camidge, Shirish M. Gadgeel, Fadlo R. Khuri, J. A. Engelman, Marianna Koczywas, Arun Rajan, Alicyn Campbell, Diana Gernhardt, Ana Ruiz-Garcı́a, Stephen P. Letrent, Jane Liang, Ian W. Taylor, Joseph O’Connell, Pasi A. Jänne	120
9	Health-Related Quality of Life in Patients with Advanced Nonsquamous Non–Small-Cell Lung Cancer Receiving Bevacizumab or Bevacizumab-Plus-Pemetrexed Maintenance Therapy in AVAPERL (MO22089) 2013 ·Journal of Thoracic Oncology ·Achim Rittmeyer, В. А. Горбунова, Anders Vikström, Arnaud Scherpereel, Joo-Hang Kim, Myung‐Ju Ahn, Antonio Chella, C. Chouaïd, Alicyn Campbell, Fabrice Barlési	23
10	Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer 2012 ·Journal of Clinical Oncology ·Suresh S. Ramalingam, Fiona Blackhall, Maciej Krzakowski, Carlos H. Barrios, Keunchil Park, Isabel Bover, Dae Seog Heo, Rafael Rosell, Denis Talbot, Richard C. Frank, Stephen P. Letrent, Ana Ruiz-Garcı́a, Ian W. Taylor, Jane Liang, Alicyn Campbell, Joseph O’Connell, Michael Boyer	211
11	PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): A phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E). 2010 ·Journal of Clinical Oncology ·Alicyn Campbell, Karen L. Reckamp, D. Ross Camidge, Giuseppe Giaccone, Shirish M. Gadgeel, Fadlo R. Khuri, Jeffrey A. Engelman, L. Denis, Joseph O’Connell, Pasi A. Jänne	36
12	PF-00299804 (PF299) in Asian patients (pts) with non-small cell lung cancer (NSCLC) refractory to chemotherapy (CT) and erlotinib (E) or gefitinib (G): A phase (P) I/II study. 2010 ·Journal of Clinical Oncology ·(unknown), D. S. Heo, (unknown), (unknown), (unknown), (unknown), Robert Millham, Alicyn Campbell, (unknown), (unknown)	20
13	Physical Activity Levels of Women Attending Glasgow Breast Clinics. 2009 ·Cancer Research ·(unknown), (unknown), Keith N. Ogston, (unknown), C. Wilson, Alicyn Campbell, Sian Tovey	1
14	Why are miraculous cures mainly of cancer? 2003 ·BMJ ·Alicyn Campbell	1
15	Earth observations for the space radar laboratory mission: Report on the student challenge awards project 1994 ·Geocarto International ·J. Way, Benjamin Holt, (unknown), V. S. Connors, (unknown), Tom Dunkley Jones, Alicyn Campbell, (unknown), (unknown), (unknown), (unknown), Jonathan Woodring, (unknown), Eric N. Mortensen, David Ouellette, Robert H. Parrott, (unknown)	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact